Kera Capital Partners Inc. Invests $1.41 Million in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)

Kera Capital Partners Inc. acquired a new stake in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 376,131 shares of the company’s stock, valued at approximately $1,407,000. Kera Capital Partners Inc. owned about 0.87% of Kyverna Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. FMR LLC purchased a new stake in shares of Kyverna Therapeutics during the 3rd quarter valued at about $33,000. Creative Planning purchased a new stake in Kyverna Therapeutics during the third quarter valued at approximately $54,000. Jacobs Levy Equity Management Inc. purchased a new stake in Kyverna Therapeutics during the third quarter valued at approximately $97,000. Federated Hermes Inc. bought a new position in Kyverna Therapeutics in the second quarter worth approximately $120,000. Finally, BNP Paribas Financial Markets grew its position in shares of Kyverna Therapeutics by 2,166.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 27,197 shares of the company’s stock valued at $133,000 after acquiring an additional 25,997 shares during the period. Institutional investors own 18.08% of the company’s stock.

Kyverna Therapeutics Price Performance

KYTX stock opened at $3.33 on Friday. The company’s fifty day moving average price is $4.32 and its 200-day moving average price is $5.99. Kyverna Therapeutics, Inc. has a one year low of $3.24 and a one year high of $35.06.

Kyverna Therapeutics (NASDAQ:KYTX) last released its quarterly earnings data on Wednesday, November 13th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.01. The company had revenue of $0.01 million for the quarter. As a group, analysts anticipate that Kyverna Therapeutics, Inc. will post -3.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently commented on KYTX. Rodman & Renshaw initiated coverage on Kyverna Therapeutics in a report on Wednesday, October 9th. They issued a “buy” rating and a $16.00 target price on the stock. HC Wainwright decreased their price objective on Kyverna Therapeutics from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 20th. UBS Group initiated coverage on Kyverna Therapeutics in a research note on Thursday, October 10th. They set a “buy” rating and a $13.00 price objective for the company. RODMAN&RENSHAW raised shares of Kyverna Therapeutics to a “strong-buy” rating in a report on Wednesday, October 9th. Finally, Wells Fargo & Company lowered their price target on shares of Kyverna Therapeutics from $44.00 to $24.00 and set an “overweight” rating on the stock in a report on Friday, November 15th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Kyverna Therapeutics has a consensus rating of “Buy” and an average target price of $25.71.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.